Naos (Salbutamol Sulfate, Ipratropium Bromide)

Salbutamol activates β2‑adrenergic receptors on airway smooth muscle, causing relaxation, while ipratropium blocks muscarinic receptors, preventing acetylcholine‑induced constriction. Together they provide a synergistic bronchodilatory effect, quickly widening the airways and enhancing airflow in obstructive lung conditions.

The specific dose and frequency of Naos are determined by the prescribing clinician based on the patient’s age, severity of disease, and response to therapy. Healthcare professionals tailor the regimen to achieve optimal bronchodilation while minimizing potential side effects.

Safety data for Naos in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss individual circumstances and consider alternative therapies when appropriate.

To request Naos, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Naos combines a short‑acting β2‑agonist (salbutamol) with an anticholinergic (ipratropium), offering dual mechanisms that can be more effective than single‑agent inhalers for certain patients. Compared with monotherapy β2‑agonists, the combination may provide faster relief and reduce the need for higher doses, while having a safety profile similar to other inhaled bronchodilators.

Naos should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the inhalation device upright and ensure the mouthpiece is clean before each use. Do not freeze the solution, and discard any product that appears discolored or contaminated.

Naos is delivered via a metered‑dose inhaler or nebulizer, depending on the formulation supplied. The patient inhales the prescribed number of puffs or nebulized doses, typically through a mouthpiece, following the device’s instructions. Proper inhalation technique—slow, deep breaths and holding the breath briefly—maximizes drug deposition in the lungs.

Serious adverse events, although rare, include paradoxical bronchospasm, severe allergic reactions such as angioedema or anaphylaxis, significant tachycardia or arrhythmias, and marked drops in blood potassium (hypokalemia). Patients should seek immediate medical attention if they experience sudden worsening of breathing, swelling of the face or throat, or rapid, irregular heartbeats.

Naos is contraindicated in individuals with known hypersensitivity to salbutamol, ipratropium, or any excipients in the formulation. It should also be avoided in patients with a history of severe paradoxical bronchospasm after inhaled bronchodilator use. Clinicians must assess each patient’s medical history before prescribing.